
The Danish Medicines Agency has received the Reimbursement Committee's final recommendation for a revision pertaining to the reimbursement scheme for insulin products – and it doesn't bode well for Novo Nordisk.
Attempts to convince the committee to change their minds have fallen short. At the beginning of November, the Danish pharmaceutical firm objected to the change to reimbursements, which would see Novo Nordisk's fast-acting insulin Fiasp receive conditional reimbursement as opposed to a general reimbursement.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app